Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Biora Therapeutics (Nasdaq: BIOR), a biotech company focused on reimagining therapeutic delivery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York, NY.
Key details of Biora's involvement include:
- A company presentation on Wednesday, September 11, 2024, at 2:00 PM Eastern time
- One-on-one investor meetings
- A live webcast of the presentation available at a provided link
A replay of the presentation will be accessible on Biora's website after the conference concludes. This participation offers Biora an opportunity to showcase its innovations and engage with potential investors in the biotech sector.
Biora Therapeutics (Nasdaq: BIOR), un'azienda biotech focalizzata sulla rimodulazione della somministrazione terapeutica, ha annunciato la sua partecipazione alla 26a Conferenza Globale sugli Investimenti Annuale H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024 a New York, NY.
I dettagli principali del coinvolgimento di Biora includono:
- Una presentazione dell'azienda mercoledì 11 settembre 2024, alle 14:00 ora orientale
- Riunioni individuali con gli investitori
- Una diretta streaming della presentazione disponibile tramite un link fornito
Una registrazione della presentazione sarà accessibile sul sito web di Biora dopo la conclusione della conferenza. Questa partecipazione offre a Biora l'opportunità di mettere in mostra le sue innovazioni e di interagire con potenziali investitori nel settore biotech.
Biora Therapeutics (Nasdaq: BIOR), una empresa biotecnológica centrada en reinventar la entrega terapéutica, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento está programado para el 9 al 11 de septiembre de 2024 en Nueva York, NY.
Los detalles clave de la participación de Biora incluyen:
- Una presentación de la empresa el miércoles 11 de septiembre de 2024, a las 2:00 PM hora del Este
- Reuniones individuales con inversores
- Una transmisión en vivo de la presentación disponible a través de un enlace proporcionado
Una repetición de la presentación estará disponible en el sitio web de Biora tras la conclusión de la conferencia. Esta participación brinda a Biora la oportunidad de mostrar sus innovaciones y relacionarse con posibles inversores en el sector biotecnológico.
비오라 테라퓨틱스 (Nasdaq: BIOR), 치료 전달 방식을 재구성하는데 집중하는 생명공학 회사가 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 열립니다.
비오라의 참여와 관련된 주요 세부사항은 다음과 같습니다:
- 회사의 발표는 2024년 9월 11일 수요일, 동부 표준시 기준 오후 2시에 진행됩니다.
- 투자가와의 일대일 미팅
- 제공된 링크를 통해 이용 가능한 발표의 라이브 웹캐스트
발표의 재생은 컨퍼런스가 종료된 후 비오라의 웹사이트에서 접근할 수 있습니다. 이번 참여는 비오라가 혁신을 선보이고 생명공학 분야의 잠재 투자자와의 교류 기회를 제공하는 계기를 마련합니다.
Biora Therapeutics (Nasdaq: BIOR), une entreprise biopharmaceutique axée sur la réinvention de la délivrance thérapeutique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale des Investissements H.C. Wainwright. L'événement est prévu pour les 9-11 septembre 2024 à New York, NY.
Les principaux détails de l'implication de Biora comprennent :
- Une présentation de l'entreprise le mercredi 11 septembre 2024 à 14h00, heure de l'Est
- Des réunions individuelles avec des investisseurs
- Un webinaire en direct de la présentation disponible via un lien fourni
Une rediffusion de la présentation sera accessible sur le site web de Biora après la conclusion de la conférence. Cette participation offre à Biora une opportunité de mettre en avant ses innovations et d'interagir avec des investisseurs potentiels dans le secteur biopharmaceutique.
Biora Therapeutics (Nasdaq: BIOR), ein Biotech-Unternehmen, das sich auf die Neugestaltung der therapeutischen Bereitstellung konzentriert, hat seine Teilnahme an der 26. Jahrestagung für globale Investitionen von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York, NY, statt.
Die wichtigsten Details zur Beteiligung von Biora umfassen:
- Eine Unternehmenspräsentation am Mittwoch, den 11. September 2024, um 14:00 Uhr Eastern Time
- Einzelgespräche mit Investoren
- Eine Live-Übertragung der Präsentation, die über einen bereitgestellten Link verfügbar sein wird
Eine Wiederholung der Präsentation wird nach der Konferenz auf Bioras Website zugänglich sein. Diese Teilnahme bietet Biora die Möglichkeit, ihre Innovationen vorzustellen und mit potenziellen Investoren im Biotech-Bereich in Kontakt zu treten.
- None.
- None.
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the H.C. Wainwright 26th Annual Global Investment Conference, September 9–11, 2024.
| H.C. Wainwright 26th Annual Global Investment Conference, New York, NY Company presentation and 1x1 investor meetings | |
| Date: | Wednesday, September 11, 2024 |
| Time: | 2:00 PM Eastern time |
| Live Webcast: | https://journey.ct.events/view/1cda5986-f016-485c-9afa-6c3bcfc9d834 |
A replay will also be available on Biora’s website following the conference.
About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free, oral delivery for better management of chronic diseases.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model-based data projections for the BT-600 program, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “envision,” “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “projects,” “projecting,” “potential,” “plan,” “goal(s),” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact
Liz Robinson
CG Life
lrobinson@cglife.com
FAQ
When is Biora Therapeutics (BIOR) presenting at the H.C. Wainwright Global Investment Conference?
Where can I watch the live webcast of Biora Therapeutics' (BIOR) presentation?
Will there be a replay available of Biora Therapeutics' (BIOR) presentation at the H.C. Wainwright conference?
What types of activities will Biora Therapeutics (BIOR) participate in at the H.C. Wainwright conference?
What is the date range for the H.C. Wainwright Global Investment Conference featuring Biora Therapeutics (BIOR)?
